Affordable Access

deepdyve-link
Publisher Website

Plasma concentrations of persistent organic pollutants and pancreatic cancer risk.

Authors
  • Porta, Miquel1, 2, 3
  • Gasull, Magda1, 2, 3
  • Pumarega, José1, 2, 3
  • Kiviranta, Hannu4
  • Rantakokko, Panu4
  • Raaschou-Nielsen, Ole5
  • Bergdahl, Ingvar A6, 7
  • Sandanger, Torkjel Manning8
  • Agudo, Antoni9
  • Rylander, Charlotta8
  • Nøst, Therese Haugdahl8
  • Donat-Vargas, Carolina10, 11
  • Aune, Dagfinn12
  • Heath, Alicia K12
  • Cirera, Lluís3, 13, 14
  • Goñi-Irigoyen, Fernando3, 15, 16
  • Alguacil, Juan3, 17
  • Giménez-Robert, Àlex1, 2
  • Tjønneland, Anne5
  • Sund, Malin18
  • And 33 more
  • 1 Hospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain. , (Spain)
  • 2 Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain. , (Spain)
  • 3 Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain. , (Spain)
  • 4 Department of Health Security, National Institute for Health and Welfare, Kuopio, Finland. , (Finland)
  • 5 Danish Cancer Society Research Center, Copenhagen, Denmark. , (Denmark)
  • 6 Department of Biobank Research, Umeå University, Umeå, Sweden. , (Sweden)
  • 7 Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. , (Sweden)
  • 8 Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway. , (Norway)
  • 9 Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. , (Spain)
  • 10 Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. , (Sweden)
  • 11 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid, CEI UAM+CSIC, Madrid, Spain. , (Spain)
  • 12 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • 13 Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. , (Spain)
  • 14 Department of Health and Social Sciences, University of Murcia, Murcia, Spain. , (Spain)
  • 15 Health Department of Basque Government, Public Health Laboratory in Gipuzkoa, San Sebastian, Spain. , (Spain)
  • 16 Health Research Institute Biodonostia, San Sebastian, Spain. , (Spain)
  • 17 University of Huelva, Huelva, Spain. , (Spain)
  • 18 Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden. , (Sweden)
  • 19 Department of Public Health, Aarhus University, Aarhus, Denmark. , (Denmark)
  • 20 CESP, Faculté de médecine (USVQ), Université Paris-Sud, INSERM, Université Paris-Saclay, Villejuif, France. , (France)
  • 21 Inserm UMR1018, Institut Gustave Roussy, Villejuif, France. , (France)
  • 22 Pancreatology Department, Beaujon Hospital, AP-HP, Clichy, France. , (France)
  • 23 Inserm UMR1149, DHU Unit, Paris-Diderot University, Paris, France. , (France)
  • 24 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. , (Germany)
  • 25 Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam, Rehbruecke, Nuthetal, Germany. , (Germany)
  • 26 Institute of Nutrition Science, University of Potsdam, Nuthetal, Germany. , (Germany)
  • 27 Hellenic Health Foundation, Athens, Greece. , (Greece)
  • 28 Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network-ISPRO, Florence, Italy. , (Italy)
  • 29 Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. , (Italy)
  • 30 Cancer Registry and Histopathology Department, "Civic-M.P. Arezzo" Hospital, ASP Ragusa, Ragusa, Italy. , (Italy)
  • 31 Molecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM), Turin, Italy. , (Italy)
  • 32 Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. , (Italy)
  • 33 Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands. , (Netherlands)
  • 34 Public Health Directorate, Asturias, Spain. , (Spain)
  • 35 Escuela Andaluza de Salud Pública (EASP), Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. , (Spain)
  • 36 National Faculty of Public Health, University of Antioquia, Medellín, Colombia. , (Colombia)
  • 37 Navarra Public Health Institute, Pamplona, Spain. , (Spain)
  • 38 IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. , (Spain)
  • 39 MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • 40 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • 41 International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France. , (France)
  • 42 Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. , (Netherlands)
  • 43 Oncology Data Analytics Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. , (Spain)
Type
Published Article
Journal
International Journal of Epidemiology
Publisher
Oxford University Press
Publication Date
May 09, 2022
Volume
51
Issue
2
Pages
479–490
Identifiers
DOI: 10.1093/ije/dyab115
PMID: 34259837
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Findings and limitations of previous studies on persistent organic pollutants (POPs) and pancreatic cancer risk support conducting further research in prospective cohorts. We conducted a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Participants were 513 pancreatic cancer cases and 1020 matched controls. Concentrations of 22 POPs were measured in plasma collected at baseline. Some associations were observed at higher concentrations of p, p'-DDT, trans-nonachlor, β-hexachlorocyclohexane and the sum of six organochlorine pesticides and of 16 POPs. The odds ratio (OR) for the upper quartile of trans-nonachlor was 1.55 (95% confidence interval 1.06-2.26; P for trend = 0.025). Associations were stronger in the groups predefined as most valid (participants having fasted >6 h, with microscopic diagnostic confirmation, normal weight, and never smokers), and as most relevant (follow-up ≥10 years). Among participants having fasted >6 h, the ORs were relevant for 10 of 11 exposures. Higher ORs were also observed among cases with microscopic confirmation than in cases with a clinical diagnosis, and among normal-weight participants than in the rest of participants. Among participants with a follow-up ≥10 years, estimates were higher than in participants with a shorter follow-up (for trans-nonachlor: OR = 2.14, 1.01 to 4.53, P for trend = 0.035). Overall, trans-nonachlor, three PCBs and the two sums of POPs were the exposures most clearly associated with pancreatic cancer risk. Individually or in combination, most of the 22 POPs analysed did not or only moderately increased the risk of pancreatic cancer. © The Author(s) 2021. Published by Oxford University Press on behalf of the International Epidemiological Association.

Report this publication

Statistics

Seen <100 times